MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2165/00002018-200124090-00005

Медицинская библиотека · Drug safety · 2001

Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring.

Layton D, Pearce G L, Shakir S A

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Unstable bladder symptoms are a common problem in general practice. Drug therapy with anticholinergic drugs is frequently used in the management of this condition. However such drugs are associated with a high incidence of anticholinergic adverse effects. Tolterodine is a competitive anticholinergic agent, selective for the bladder as opposed to the salivary glands.

OBJECTIVE

To monitor the safety of tolterodine as used in general practice patients in England for the treatment of urinary frequency, urgency and incontinence.

DESIGN

Prospective observational cohort study.

PATIENTS AND

PARTICIPANTS

14,526 patients [mean age 62.7 (SD 16.4) years; 68.6% female].

METHODS

Patients prescribed tolterodine in general practice, soon after the release of the drug in the UK, were followed up for a minimum of 6 months using the technique of prescription-event monitoring (PEM).

RESULTS

The most common adverse events reported were dry mouth, headache, malaise, constipation, dyspepsia, nausea and vomiting and pain in abdomen. We identified some uncommon events as possible adverse drug reactions--notably hallucinations, tachycardia and palpitations. The prevalence of these events was compared with that in patient cohorts for other drugs on the PEM database. The age- and sex-adjusted relative risk of hallucinations on tolterodine compared with 10 drugs of other therapeutic classes, and with terodiline, another drug indicated for bladder instability, was 4.85 [95% confidence interval (CI) 2.72 to 8.66] and 1.25 (95% CI 0.62 to 2.53), respectively. There was no significant difference for tachycardia/palpitation in this comparison.

CONCLUSIONS

Tolterodine is well tolerated in general practice at the recommended daily dose. Hallucinations, tachycardia and palpitations are infrequently associated with the drug.

Для цитирования: Layton D, Pearce G L, Shakir S A. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring.. Drug safety. 2001. DOI: 10.2165/00002018-200124090-00005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.